Deutsche Bank Analysts Give Novartis (VTX:NOVN) a CHF 90 Price Target

Deutsche Bank set a CHF 90 target price on Novartis (VTX:NOVN) in a report issued on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

NOVN has been the topic of several other research reports. Barclays reaffirmed a buy rating and set a $417.00 target price on shares of Boeing in a report on Monday, April 8th. Jefferies Financial Group increased their target price on shares of Nice to $166.00 and gave the company a buy rating in a report on Thursday, May 16th. HSBC set a €101.00 ($117.44) target price on shares of Grenke and gave the company a buy rating in a report on Thursday, April 25th. Credit Suisse Group reduced their target price on shares of FOX from $51.00 to $45.00 and set an outperform rating on the stock in a report on Monday, June 3rd. Finally, Goldman Sachs Group began coverage on shares of Enbridge in a report on Thursday. They set a neutral rating on the stock. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of CHF 88.64.

Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Read More: Fundamental Analysis and Individual Investors

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.